<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00917826</url>
  </required_header>
  <id_info>
    <org_study_id>P2 L-D AB</org_study_id>
    <nct_id>NCT00917826</nct_id>
  </id_info>
  <brief_title>Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies</brief_title>
  <official_title>A Phase II Trial of Low-Dose Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+)Lymphoid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HemaQuest Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>HemaQuest Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess whether administration of Arginine Butyrate +
      ganciclovir/valganciclovir for up to three 21-day cycles is tolerable, and results in partial
      or complete responses in patients with EBV(+) lymphoid malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2008</start_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate (using Revised Response Criteria for Malignant Lymphoma, Cheson et al., JCO 2007)</measure>
    <time_frame>Every three weeks. If a response is recorded evaluation continues until an objective determination of disease progression is made (assessment may continue after treatment is discontinued.)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Rate (using Revised Response Criteria for Malignant Lymphoma, Cheson et al., JCO 2007)</measure>
    <time_frame>Every three weeks. If a response is recorded evaluation continues until an objective determination of disease progression is made (assessment may continue after treatment is discontinued.)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by (1) adverse events, (2) laboratory values (3) vital signs (4) physical exam</measure>
    <time_frame>Up to three 21-day cycles. If a response is recorded evaluation continues until an objective determination of disease progression is made (assessments may continue after treatment is discontinued.)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>EBV Lymphomas</condition>
  <condition>Lympho-proliferative Diseases</condition>
  <arm_group>
    <arm_group_label>Arginine Butyrate + Ganciclovir/Valganciclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine Butyrate</intervention_name>
    <description>1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)</description>
    <arm_group_label>Arginine Butyrate + Ganciclovir/Valganciclovir</arm_group_label>
    <other_name>HQK-1004</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganciclovir</intervention_name>
    <description>5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)</description>
    <arm_group_label>Arginine Butyrate + Ganciclovir/Valganciclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir</intervention_name>
    <description>900 mg BID for 16 days (Days 6-21 of each 21 day cycle)</description>
    <arm_group_label>Arginine Butyrate + Ganciclovir/Valganciclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 3 years. (No dosing or adverse event data are currently available on the use of
             valganciclovir in patients &lt; 16 years of age.)

          -  Life expectancy of &gt; 3 months.

          -  ECOG Performance Status 0-2 or Karnofsky Performance Scale ≥ 60%.

          -  Baseline (untransfused) HbF level &gt; 2%

          -  Normal organ and marrow function defined as: (i) absolute neutrophil count of ≥
             1,000/µL. (ii) platelets ≥ 50,000/ µL. (iii) total bilirubin of ≤ 2.0 x upper limit of
             normal. (iv) AST (SGOT)/ALT(SGPT) of ≤ 2.0 x institutional upper limit of normal. (v)
             creatinine within normal range for institution.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             prior to study entry and for the duration of study participation.

          -  Able and willing to give informed consent.

        Exclusion Criteria:

          -  Patients that have received chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entry, or those who have not recovered form
             adverse events due to agents administered 4 weeks earlier.

          -  Patients may not be receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Arginine Butyrate, ganciclovir or valganciclovir.

          -  Patients who have an acute myocardial infarction or onset of atrial fibrillation
             within the past 6 months.

          -  Uncontrolled intercurrent illness including, but not limited to , ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Tumor impinging on an organ or anatomical structure deemed critical by the
             investigator.

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Lerner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University School of Mediciine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2009</study_first_submitted>
  <study_first_submitted_qc>June 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2009</study_first_posted>
  <disposition_first_submitted>July 28, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 1, 2011</disposition_first_posted>
  <last_update_submitted>July 28, 2011</last_update_submitted>
  <last_update_submitted_qc>July 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Susan Perrine, M.D. Chief Scientific Officer, VP Clinical Affairs</name_title>
    <organization>HemaQuest Pharmaceuticals Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganciclovir</mesh_term>
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir triphosphate</mesh_term>
    <mesh_term>Butyric Acid</mesh_term>
    <mesh_term>Arginine butyrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

